Developing a Decision Aid for Lung Cancer Patients

Shared Decision Making in Patients With Lung Cancer After Surgery：a Molecular Testing Decision Aid Evidence Based Development Study

This study is trying to create a helpful tool for lung cancer patients to make better decisions about their treatment options by gathering input from patients and healthcare experts.

Quick facts

• Study type: Observational
• Enrollment: 190 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Sichuan Cancer Hospital and Research Institute (Academic / other)
• Locations: 1 site (Chengdu, Sichuan)
• Trial ID: NCT05191485 on ClinicalTrials.gov

What this trial studies

This study aims to create a Decision Aid for Lung Cancer Molecular Testing (DA_LCMT) to enhance shared decision-making for patients diagnosed with lung adenocarcinoma. Utilizing qualitative research methods, the study will gather insights from patients and various stakeholders, including healthcare professionals and insurance representatives, to identify their decision-making needs. The DA_LCMT will undergo multiple revisions through structured interviews and testing phases to ensure its effectiveness and relevance. The study follows established frameworks to ensure that the decision aid aligns with patient priorities and preferences.

Who should consider this trial

Good fit: Ideal candidates include adults aged 18 and older diagnosed with primary invasive adenocarcinoma of the lung who are considering molecular testing.

Not a fit: Patients who do not have lung adenocarcinoma or those who are not involved in the decision-making process regarding molecular testing may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could empower lung cancer patients to make more informed decisions regarding molecular testing, potentially improving their treatment outcomes.

How similar studies have performed: While the approach of developing decision aids is established, this specific application in lung cancer molecular testing is relatively novel.

Eligibility criteria

Inclusion criteria:

Patients of decision-making need assessment:

1\) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have or have not made a decision on lung cancer molecular testing (whether to perform molecular testing or not).

Other stakeholders of decision-making need assessment:

1\) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) for thoracic surgeons and personnel in molecular testing companies: have previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; 4) for nurses, hospital administrators, and personnel in insurance companies: have a certain understanding of the decision-making process.

Patients of Cognitive debriefing/Alpha tests:

1\) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have made a decision on whether to perform lung cancer molecular testing or not.

other stakeholders of Cognitive debriefing/Alpha tests:

1\) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) for thoracic surgeons and personnel in molecular testing companies: have previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; 4) for nurses, hospital administrators, and personnel in insurance companies: have a certain understanding of the decision-making process.

Patients of field testing /Beta tests:

1\) age ≥ 18 years; 2) patients with primary invasive adenocarcinoma of lung diagnosed by intraoperative frozen pathological section; 3) have not decided whether to perform lung cancer molecular testing or not.

Clinician of field testing /Beta tests:

1\) age ≥ 18 years; 2) relevant work experience ≥ 2 years; 3) previous experience in communicating with patients about molecular testing related to lung cancer targeted therapy; and 4) voluntarily participated in this study.

Exclusion criteria:

Inability to understand the research content.

Where this trial is running

Chengdu, Sichuan

• Sichuan Cancer Hospital & Institute — Chengdu, Sichuan, China (Recruiting)

Conditions Surgery; Lung Adenocarcinoma; Shared-decision making; Decision aid